Desano

Shanghai Desano Chemical Pharmaceutical Co., Ltd. is a pharmaceutical company focused on the research, development, manufacturing, and sale of pharmaceutical drugs. Initially established in 1996 and headquartered in Shanghai's Zhangjiang Hi-tech Park, the company concentrates on therapeutic areas for global public health diseases, particularly HIV and malaria. Desano operates as a manufacturer of branded generic Active Pharmaceutical Ingredients (APIs) and Finished Pharmaceutical Products (FPPs).

The company's business model involves supplying key APIs to manufacturers of finished drug products and producing its own formulations. Its product catalog includes drugs such as Lamivudine, Tenofovir, Efavirenz, Artemether, and Artesunate. Desano serves a global market, with export markets that include Russia, Vietnam, and India. The company reports that it supports the treatment of over 6 million patients annually through its supply of antiretroviral (ARV) products. Desano has received certifications and passed inspections from multiple international regulatory bodies, including the US FDA, WHO, and European Medicines Agency.

Desano has established four manufacturing sites for formulations, APIs, and intermediates in Shanghai and Jiangsu Province. The company also maintains a significant R&D presence, with its Shanghai R&D center recognized as a National High-Tech Research & Development Center and a National R&D and Engineering center for Anti-HIV Drugs. This center employs over 100 professionals specializing in various aspects of pharmaceutical development. In 2012, the company incorporated Desano Pharmaceuticals Private Limited in India, a step-down subsidiary, to establish a manufacturing facility for anti-diabetic and anti-retroviral APIs and formulations. Key leadership includes Li Jingpeng as President.

Keywords: Active Pharmaceutical Ingredients, Finished Pharmaceutical Products, antiretroviral drugs, anti-malarial drugs, generic pharmaceuticals, HIV treatment, malaria treatment, pharmaceutical manufacturing, cGMP manufacturing, pharmaceutical R&D, Shanghai, China, US FDA approved, WHO prequalification, EDQM, global public health, pharmaceutical exports, Tenofovir, Lamivudine, Efavirenz, Artemether